New drug may shield heart surgery patients from deadly complications
NCT ID NCT07594509
First seen May 26, 2026 · Last updated Jun 20, 2026 · Updated 5 times
Summary
This study tests whether the drug vericiguat can prevent serious heart and organ problems in people undergoing heart surgery. About 600 high-risk patients will receive either vericiguat plus standard care or standard care alone. The goal is to see if vericiguat reduces early complications like low cardiac output, heart injury, and major adverse events within a year.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for CARDIOPULMONARY BYPASS are added.
Genom att skicka in godkänner du våra Användarvillkor
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
Genom att skicka in godkänner du våra Användarvillkor
Study contacts
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
Locations
-
The First Affiliated Hospital of Nanjing Medical University
Nanjing, Jiangsu, 210029, China
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
Active substance
Vericiguat
What this could lead to
If it works, this could lead to a new standard treatment to prevent serious heart and organ damage after cardiovascular surgery.
What could go wrong
This trial hasn't started yet, and it's not a cure—it aims to reduce complications. Results may not apply to all surgery types or patients.
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.